Switch to:
Also traded in: Denmark, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
GNMSF's Cash-to-Debt is ranked higher than
88% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. GNMSF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GNMSF' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.41  Med: 119.87 Max: 29603.64
Current: No Debt
8.41
29603.64
Equity-to-Asset 0.92
GNMSF's Equity-to-Asset is ranked higher than
88% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GNMSF: 0.92 )
Ranked among companies with meaningful Equity-to-Asset only.
GNMSF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.23  Med: 0.72 Max: 0.93
Current: 0.92
0.23
0.93
Interest Coverage 37.80
GNMSF's Interest Coverage is ranked lower than
76% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNMSF: 37.80 )
Ranked among companies with meaningful Interest Coverage only.
GNMSF' s Interest Coverage Range Over the Past 10 Years
Min: 17.98  Med: 4942.88 Max: N/A
Current: 37.8
Piotroski F-Score: 6
Altman Z-Score: 115.91
WACC vs ROIC
8.19%
608.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 57.97
GNMSF's Operating Margin % is ranked higher than
97% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. GNMSF: 57.97 )
Ranked among companies with meaningful Operating Margin % only.
GNMSF' s Operating Margin % Range Over the Past 10 Years
Min: -104.29  Med: -25.85 Max: 64.46
Current: 57.97
-104.29
64.46
Net Margin % 65.36
GNMSF's Net Margin % is ranked higher than
97% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. GNMSF: 65.36 )
Ranked among companies with meaningful Net Margin % only.
GNMSF' s Net Margin % Range Over the Past 10 Years
Min: -172.46  Med: -63.82 Max: 67.39
Current: 65.36
-172.46
67.39
ROE % 30.41
GNMSF's ROE % is ranked higher than
96% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. GNMSF: 30.41 )
Ranked among companies with meaningful ROE % only.
GNMSF' s ROE % Range Over the Past 10 Years
Min: -112.03  Med: -22.07 Max: 30.41
Current: 30.41
-112.03
30.41
ROA % 27.56
GNMSF's ROA % is ranked higher than
97% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. GNMSF: 27.56 )
Ranked among companies with meaningful ROA % only.
GNMSF' s ROA % Range Over the Past 10 Years
Min: -36.89  Med: -13.49 Max: 27.56
Current: 27.56
-36.89
27.56
ROC (Joel Greenblatt) % 788.35
GNMSF's ROC (Joel Greenblatt) % is ranked higher than
98% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. GNMSF: 788.35 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNMSF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -675.71  Med: -26.15 Max: 2780.55
Current: 788.35
-675.71
2780.55
3-Year Revenue Growth Rate 32.00
GNMSF's 3-Year Revenue Growth Rate is ranked higher than
79% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. GNMSF: 32.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GNMSF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 12.75 Max: 326.8
Current: 32
0
326.8
3-Year EBITDA Growth Rate 130.00
GNMSF's 3-Year EBITDA Growth Rate is ranked higher than
99% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. GNMSF: 130.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
GNMSF' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.7  Med: -12.65 Max: 130
Current: 130
-47.7
130
3-Year EPS without NRI Growth Rate 142.40
GNMSF's 3-Year EPS without NRI Growth Rate is ranked higher than
99% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. GNMSF: 142.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
GNMSF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36  Med: -16.3 Max: 142.4
Current: 142.4
-36
142.4
GuruFocus has detected 1 Warning Sign with Genmab A/S $GNMSF.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:SGEN, NAS:ALKS, OTCPK:NVZMF, NAS:JAZZ, NAS:TSRO, OTCPK:UCBJY, NAS:BMRN, OTCPK:SBMFF, NAS:EXEL, NAS:UTHR, NAS:BIVV, OTCPK:GIKLY, NAS:IONS, NAS:ARIA, NAS:ALNY, NAS:KITE, NAS:ACAD, NAS:GLPG, NAS:TECH, NAS:NBIX » details
Traded in other countries:GEN.Denmark, GE9.Germany, 0MGB.UK,
Headquarter Location:Denmark
Genmab A/S is a biotechnology company which creates and develops differentiated antibody therapeutics focused on the treatment of cancer. Its marketed product include DARZALEX and Arzerra.

Genmab A/S.

Top Ranked Articles about Genmab A/S

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2017
Phase II Study of Daratumumab in Non-Hodgkin’s Lymphoma Will Not Proceed to Stage 2 of Trial
Company Announcement

Phase II study (CARINA, LYM2001) in NHL will not proceed
Other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned
Copenhagen, Denmark; March 30, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that its collaboration partner for daratumumab, Janssen Biotech, Inc., has decided not to initiate stage 2 of the Phase II study (CARINA, LYM2001) of daratumumab in three types of relapsed or refractory non-Hodgkin’s lymphoma (NHL).  The study will not proceed to stage 2 as a data review showed that two cohorts of the study, investigating the use of daratumumab monotherapy in relapsed or refractory patients with follicular lymphoma (FL), and with diffuse large B-cell lymphoma (DLBCL) did not reach the predefined futility thresholds of overall response rates (ORR) of 50%, and 30%, respectively.  In the third cohort in the study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment, driven by the aggressive nature of the disease in its final stages. This has no impact on other ongoing or planned studies with daratumumab. “While we hoped that daratumumab as a monotherapy could potentially provide a new treatment option in NHL patients with a high unmet medical need, the preliminary activity profile seen was not sufficient for the study to continue. Daratumumab is still being investigated in a number of indications including multiple myeloma and other hematological cancers such as NK/T-cell lymphoma and myelodysplastic syndrome as well as in solid tumors,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. About the CARINA LYM2001 study

The Phase II study (NCT02413489) is a three arm (DLBCL, FL, MCL), open-label multicenter study, which planned to enroll up to 210 patients in 2 stages with relapsed or refractory non-Hodgkin’s lymphoma. Stage 1 of the study was designed to provide a preliminary assessment of monotherapy activity, with stage 2 designed to further evaluate safety and efficacy of daratumumab monotherapy. Stage 2 will now not proceed. The primary endpoint of the study was overall response rate. The safety profile of daratumumab in these diseases was also assessed. About DARZALEX® (daratumumab)

DARZALEX® (daratumumab) injection for intravenous infusion is indicated in the United States in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy and as a monotherapy for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 DARZALEX is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration (FDA) approval to treat multiple myeloma. DARZALEX is indicated in Europe for use as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a PI and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.  For more information, visit www.DARZALEX.com.   Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.  Daratumumab triggers a person’s own immune system to attack the cancer cells, resulting in rapid tumor cell death through multiple immune-mediated mechanisms of action and through immunomodulatory effects, in addition to direct tumor cell death, via apoptosis (programmed cell death).1,2,3,4,5 Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab. Five Phase III clinical studies with daratumumab in relapsed and frontline multiple myeloma settings are currently ongoing, and additional studies are ongoing or planned to assess its potential in other malignant and pre-malignant diseases on which CD38 is expressed, such as smoldering myeloma, NK/T-cell lymphoma, amyloidosis, myelodysplastic syndromes and solid tumors.  Daratumumab has received two Breakthrough Therapy Designations from the U.S. FDA, for multiple myeloma, as both a monotherapy and in combination with other therapies.   

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.    Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: 45 33 44 77 20; M: 45 25 12 62 60; E: [email protected]



This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.



Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc. 1 FDA 2015. Daratumumab Prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/761036Orig1s000lbledt.pdf. Last accessed December 2016. 2 De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. The Journal of Immunology. 2011; 186: 1840-1848. 3 Overdijk, MB, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015; 7: 311-21. 4 Krejcik, MD et al. Daratumumab Depletes CD38 Immune-regulatory Cells, Promotes T-cell Expansion, and Skews T-cell Repertoire in Multiple Myeloma. Blood. 2016; 128: 384-94. 5 Jansen, JH  et al. Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. Blood. 2012;120(21):abstract 2974. Company Announcement no. 13

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122 Genmab A/S

Bredgade 34E

1260 Copenhagen K

DenmarkAttachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/4b6d8610-c874-4e82-8a3a-659cc3450785


Read more...
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees in Genmab
Company Announcement



Following Genmab A/S’ (Nasdaq Copenhagen: GEN) Annual General Meeting held on March 28, 2017, the Company’s Board of Directors met to constitute itself. Mats Pettersson was appointed Chairman and Dr. Anders Gersel Pedersen was appointed Deputy Chairman. It was decided to grant 2,883 restricted stock units and 8,736 warrants to employees of the Company and the Company’s subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,402. The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted by the shareholders at the annual general meeting. Information concerning Genmab's restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units. The exercise price for each warrant is DKK 1,402. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 465.14. The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants were granted pursuant to the warrant plan adopted by the board on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants. About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.



Contact:         

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: 45 33 44 77 20; M: 45 25 12 62 60; E: [email protected] This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc. Company Announcement no. 11

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122 Genmab A/S

Bredgade 34E

1260 Copenhagen K

DenmarkAttachments: http://www.globenewswire.com/NewsRoom/AttachmentNg/b9185d2c-df1c-4da8-98ec-510599cab7d8


Read more...

Ratios

vs
industry
vs
history
PE Ratio 67.93
GNMSF's PE Ratio is ranked lower than
78% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. GNMSF: 67.93 )
Ranked among companies with meaningful PE Ratio only.
GNMSF' s PE Ratio Range Over the Past 10 Years
Min: 42.72  Med: 84.05 Max: 133.3
Current: 67.93
42.72
133.3
PE Ratio without NRI 67.93
GNMSF's PE Ratio without NRI is ranked lower than
78% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. GNMSF: 67.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
GNMSF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 42.64  Med: 84.05 Max: 181.04
Current: 67.93
42.64
181.04
Price-to-Owner-Earnings 285.87
GNMSF's Price-to-Owner-Earnings is ranked lower than
91% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. GNMSF: 285.87 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GNMSF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 124.69  Med: 303.69 Max: 712.66
Current: 285.87
124.69
712.66
PB Ratio 16.29
GNMSF's PB Ratio is ranked lower than
93% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. GNMSF: 16.29 )
Ranked among companies with meaningful PB Ratio only.
GNMSF' s PB Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.71 Max: 25.04
Current: 16.29
1.63
25.04
PS Ratio 44.32
GNMSF's PS Ratio is ranked lower than
76% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. GNMSF: 44.32 )
Ranked among companies with meaningful PS Ratio only.
GNMSF' s PS Ratio Range Over the Past 10 Years
Min: 3.08  Med: 15.5 Max: 68.87
Current: 44.32
3.08
68.87
Price-to-Free-Cash-Flow 274.04
GNMSF's Price-to-Free-Cash-Flow is ranked lower than
96% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. GNMSF: 274.04 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GNMSF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.77  Med: 116.36 Max: 4518.94
Current: 274.04
3.77
4518.94
Price-to-Operating-Cash-Flow 246.23
GNMSF's Price-to-Operating-Cash-Flow is ranked lower than
96% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. GNMSF: 246.23 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GNMSF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.67  Med: 124.44 Max: 1512.17
Current: 246.23
3.67
1512.17
EV-to-EBIT 66.08
GNMSF's EV-to-EBIT is ranked lower than
86% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. GNMSF: 66.08 )
Ranked among companies with meaningful EV-to-EBIT only.
GNMSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -390.3  Med: 14.1 Max: 1482
Current: 66.08
-390.3
1482
EV-to-EBITDA 66.08
GNMSF's EV-to-EBITDA is ranked lower than
84% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. GNMSF: 66.08 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNMSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1007.1  Med: 9.9 Max: 1482
Current: 66.08
-1007.1
1482
Current Ratio 11.90
GNMSF's Current Ratio is ranked higher than
84% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. GNMSF: 11.90 )
Ranked among companies with meaningful Current Ratio only.
GNMSF' s Current Ratio Range Over the Past 10 Years
Min: 1.4  Med: 3.67 Max: 17.04
Current: 11.9
1.4
17.04
Quick Ratio 11.90
GNMSF's Quick Ratio is ranked higher than
84% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GNMSF: 11.90 )
Ranked among companies with meaningful Quick Ratio only.
GNMSF' s Quick Ratio Range Over the Past 10 Years
Min: 1.4  Med: 3.67 Max: 17.04
Current: 11.9
1.4
17.04

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.20
GNMSF's 3-Year Average Share Buyback Ratio is ranked higher than
69% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. GNMSF: -5.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNMSF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.9  Med: -5.5 Max: -0.2
Current: -5.2
-19.9
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 22.40
GNMSF's Price-to-Net-Cash is ranked lower than
84% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. GNMSF: 22.40 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GNMSF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 10.42  Med: 20.13 Max: 75.2
Current: 22.4
10.42
75.2
Price-to-Net-Current-Asset-Value 17.53
GNMSF's Price-to-Net-Current-Asset-Value is ranked lower than
83% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. GNMSF: 17.53 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GNMSF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.89  Med: 10.11 Max: 17.67
Current: 17.53
2.89
17.67
Price-to-Tangible-Book 16.93
GNMSF's Price-to-Tangible-Book is ranked lower than
89% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. GNMSF: 16.93 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GNMSF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.41  Med: 4.78 Max: 16.93
Current: 16.93
0.41
16.93
Price-to-Intrinsic-Value-Projected-FCF 20.78
GNMSF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
86% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. GNMSF: 20.78 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GNMSF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 18.68  Med: 20.41 Max: 55.86
Current: 20.78
18.68
55.86
Price-to-Median-PS-Value 2.86
GNMSF's Price-to-Median-PS-Value is ranked lower than
89% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. GNMSF: 2.86 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNMSF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 1.56 Max: 6.74
Current: 2.86
0.31
6.74
Price-to-Graham-Number 7.15
GNMSF's Price-to-Graham-Number is ranked lower than
85% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. GNMSF: 7.15 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GNMSF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 5.63  Med: 6.88 Max: 10.79
Current: 7.15
5.63
10.79
Earnings Yield (Greenblatt) % 1.51
GNMSF's Earnings Yield (Greenblatt) % is ranked higher than
72% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. GNMSF: 1.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNMSF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 1.2 Max: 374.9
Current: 1.51
0.1
374.9

More Statistics

Revenue (TTM) (Mil) $265.3
EPS (TTM) $ 2.77
Beta0.28
Short Percentage of Float0.00%
52-Week Range $141.25 - 207.50
Shares Outstanding (Mil)60.25
» More Articles for GNMSF

Headlines

Articles On GuruFocus.com
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2017 Apr 18 2017 
Phase II Study of Daratumumab in Non-Hodgkin’s Lymphoma Will Not Proceed to Stage 2 of Trial Mar 30 2017 
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrant Mar 28 2017 

More From Other Websites
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2017 Apr 18 2017
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : April 3, 2017 Apr 03 2017
Phase II Study of Daratumumab in Non-Hodgkin’s Lymphoma Will Not Proceed to Stage 2 of Trial Mar 30 2017
Grant of Restricted Stock Units to two new Board Members and Grant of Restricted Stock Units and... Mar 29 2017
Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and... Mar 28 2017
Genmab A/S :GNMSF-US: Earnings Analysis: Q4, 2016 By the Numbers : February 28, 2017 Feb 28 2017
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed or Refractory... Feb 24 2017
Genmab 2016 Annual Report Feb 22 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer Feb 08 2017
Genmab Announces Updated 2016 Financial Guidance Feb 06 2017
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : January 6, 2017 Jan 06 2017
Why Genmab (GNMSF) Might Be a Diamond in the Rough Dec 16 2016
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : December 6, 2016 Dec 06 2016
Genmab A/S (GNMSF): Strong Industry, Solid Earnings Estimate Revisions Dec 01 2016
Why Genmab (GNMSF) Could Shock the Market Soon Nov 28 2016
Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)